FDA warns Skin Authority that its skinauthority Hyperpigmentation Treatment is an unapproved and misbranded skin-bleaching drug.
What happened
FDA reviewed the label for skinauthority® Hyperpigmentation Treatment and found claims that it is a skin lightener/whitening agent with hydroquinone 2% intended to fade spots, freckles, and hyperpigmentation. FDA determined the product is a drug intended for skin bleaching and that it is an unapproved new drug and misbranded. The letter does not describe an inspection.
What FDA found
The product is a new drug marketed without an FDA-approved drug application.
Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The product is misbranded because it is a nonprescription drug subject to section 505G but does not meet those requirements and has no approved application.
Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)Skin bleaching products with hydroquinone were proposed as not generally recognized as safe and effective, so this product is deemed a new drug requiring approval since September 23, 2020.
Section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4)Introducing the unapproved drug into interstate commerce is prohibited.
Section 301(d) of the FD&C Act, 21 U.S.C. 331(d)Introducing the misbranded drug into interstate commerce is prohibited.
Section 301(a) of the FD&C Act, 21 U.S.C. 331(a)
What FDA wants
FDA asks the company to respond in writing within 15 working days describing what it has done to correct the violations and prevent recurrence, or explain why it believes the product is not in violation.
Who should pay attention
- cosmetic and skincare brands selling skin-lightening products
- retailers and online marketplaces listing hydroquinone products
- contract manufacturers and suppliers of OTC skin-bleaching drugs
This is a summary. Read the original letter on fda.gov.